Home › All Companies › CLDX › Annual Report

Celldex Therapeutics, Inc. (CLDX) — Annual Report

AI-Powered SEC Filing Analysis

← All CLDX filings
Latest Annual Report Filed: 2026-02-25

Key Insights

  • Celldex Therapeutics reported consistent revenue growth across its key programs, including Cdx622 and Barzolvolimab Anti-Kit, indicating strong pipeline progress.
  • The company's investment in research and development, as well as general and administrative expenses, suggests a focus on advancing its drug candidates through clinical development.
  • Celldex's collaborations with institutions like Rockefeller University and Yale University highlight its commitment to strategic partnerships to drive innovation.
Sentiment: Positive Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-02-25. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Celldex Therapeutics, Inc.

Quarterly Report Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.